Clinical Success For Alzheimer’s Drug Worst In Last Decade

These results related to Alzheimer’s condition have been a story of the past and it is believed that various significant clinical researches are in their initial stages of development.

Washington, DC (I-Newswire) October 23, 2012 - Medical intervention in the field of Alzheimer’s therapeutic needs has been the most unsuccessful in the clinical world as only 3 medications have been approved till date from the last 13 years for treatment of this deadly brain disease.

The research in this field of clinical illness after the recent unsuccessful stories of two significant phase III clinical trial programs has caused a significant impact on the therapeutic profile of the drug manufacturing industries.

The pharmaceutical experts on the other hand claim that this failure rate has lend a message to the researchers to turn their scientific mistakes into big victories by learning from it and working on the accurate path.

The clinical professionals have claimed that the research allied to Alzheimer’s drug has revealed a terrible track record in R&D right from the year 1998 – 2011 as around 101 medications related to this condition have either been scrapped down or paused.

This 13 year hitch has resulted in a miserable win-to-loss ratio of an approximately 1 to 34 and thus, only 3 therapeutic medications out of the overall 101 have been approved by the pharmaceutical research and manufacturing companies all over the world.

As per some research group, there are around 93 medications in the pipeline pertaining to Alzheimer’s treatment and other mental stressful conditions such as dementia.

Also, around 5.4 million Americans have access to only 5 clinically approved medications for curing the symptoms associated with the disease and no therapeutic drugs that can reverse the progression of the disease.

For More please visit our site http://www.zeepharmacy.com
Zeepharmacy
1600 Pennsylvania Ave,
Washington, DC,
USA,
20002.